WuXi Advanced Therapies Revenue and Competitors
Estimated Revenue & Valuation
- WuXi Advanced Therapies's estimated annual revenue is currently $81.5M per year.
- WuXi Advanced Therapies's estimated revenue per employee is $155,000
- WuXi Advanced Therapies has 526 Employees.
- WuXi Advanced Therapies grew their employee count by 12% last year.
What Is WuXi Advanced Therapies?
Accelerating the Progress and Time to Market of Bio-Based Drugs through Integrated Manufacturing and Laboratory Testing Services Our Story By leveraging platforms and integrated testing, the Advanced Therapies business unit of WuXi AppTec is a streamlined Contract Development and Manufacturing Organization (CDMO), pioneering the expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models. Our solutions help clients overcome challenges to commercialization, including process development, manufacturing capacity, analytical development, and raw materials management. Multiple, scale-able, enabling platforms integrate manufacturing, process development and testing capabilities to provide greater predictability and speed to clinic. Well positioned for growth, our investments in personnel and manufacturing continue to expand clinical and commercial capacities. Since 2004, WuXi AppTec has supported Advanced Therapy programs with an extensive infrastructure of state-of-the-art, GMP-compliant facilities, providing centers of excellence for manufacturing and testing. Our Vision To significantly contribute to the growth of Advanced Therapies by accelerating and transforming development and manufacturing through our enabling platforms and technologies to the benefit of patients worldwide.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
WuXi Advanced Therapies News
The CDMO unit of Wuxi AppTec, WuXi ATU, is partnering with a Singapore research group to advance cell and gene therapy manufacturing in the Asia...
WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region.
SINGAPORE, April 28, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, and A*STAR's...
The safe delivery of genetic cargo has preoccupied gene therapy for at .... the Chinese company WuXi Advanced Therapies, Novasep, Vigene ...
3, 2019 /PRNewswire/ -- WuXi AppTec today announced its launch of ... to advance discoveries and deliver groundbreaking treatments to ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|